Vertex Pharmaceuticals price target raised to $340 from $300 at Stifel

Stifel raised the firm’s price target on Vertex Pharmaceuticals to $340 from $300 and keeps a Hold rating on the shares following what the firm describes as "an in-line quarter." In terms of the pipeline, the firm’s "greatest interest" is in VX-548 for chronic pain, which it describes as having "the clearest path to blockbuster potential if successful," while other programs like T1D, APOL1, AATD, "remain interesting but high risk," the analyst tells investors.